Sangamo Therapeutics, Inc. is focused on translating ground-breaking science into genomic medicines with the potential to transform patients' lives using the Company's platform technologies in genome editing, gene therapy, gene regulation and cell therapy. In 2018, Sangamo acquired TxCell, a leader in the development of CAR-Treg cells for the treatment of inflammatory and autoimmune disorders.
Thermo Fisher Scientific
Thermo Fisher Scientific is the world leader in serving science, generating $19.8 billion in annual revenue. Customers worldwide trust our tools and solutions to help them accelerate innovation and enhance productivity – from bench to clinic. Together, we’re making advancements that make a real difference. We do that by providing an unmatched combination of innovative technologies, purchasing convenience and comprehensive support that you can expect from our premier, Gibco and Cell Therapy Systems (CTS) brands.